Half-year report · Q2
3349.TEDINET S100V2YT
Period2024-06-01 → 2024-11-30
Filed2025-01-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥505.9bn | 2024-06-01 → 2024-11-30 | Cons. | Net sales |
| Revenue | ¥965.0bn | 2023-06-01 → 2024-05-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥476.4bn | 2023-06-01 → 2023-11-30 | Cons. | Net sales |
| Operating income | ¥20.3bn | 2024-06-01 → 2024-11-30 | Cons. | Operating income |
| Operating income | ¥15.8bn | 2023-06-01 → 2023-11-30 | Cons. | Operating income |
| Ordinary income | ¥21.8bn | 2024-06-01 → 2024-11-30 | Cons. | Ordinary income |
| Ordinary income | ¥34.3bn | 2023-06-01 → 2024-05-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥17.3bn | 2023-06-01 → 2023-11-30 | Cons. | Ordinary income |
| Profit before tax | ¥21.4bn | 2024-06-01 → 2024-11-30 | Cons. | Income before income taxes |
| Profit before tax | ¥17.2bn | 2023-06-01 → 2023-11-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥14.4bn | 2024-06-01 → 2024-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥24.5bn | 2023-06-01 → 2024-05-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥11.6bn | 2023-06-01 → 2023-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥14.4bn | 2024-06-01 → 2024-11-30 | Cons. | Profit loss |
| Net income | ¥11.6bn | 2023-06-01 → 2023-11-30 | Cons. | Profit loss |
| Total assets | ¥486.6bn | at 2024-11-30 | Cons. | Assets |
| Total assets | ¥476.5bn | at 2024-05-31 | Cons. | Assets |
| Total assets | ¥436.2bn | at 2023-11-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥243.1bn | at 2024-11-30 | Cons. | Liabilities |
| Total liabilities | ¥245.1bn | at 2024-05-31 | Cons. | Liabilities |
| Net assets / equity | ¥243.5bn | at 2024-11-30 | Cons. | Net assets |
| Net assets / equity | ¥231.4bn | at 2024-05-31 | Cons. | Net assets |
| Net assets / equity | ¥220.9bn | at 2023-11-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥39.1bn | at 2024-11-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥52.3bn | at 2024-05-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥39.1bn | at 2024-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥52.3bn | at 2024-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥29.7bn | at 2023-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥45.9bn | at 2023-05-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥15.1bn | 2024-06-01 → 2024-11-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥55.2bn | 2023-06-01 → 2024-05-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥16.9bn | 2023-06-01 → 2023-11-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥22.5bn | 2024-06-01 → 2024-11-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥57.3bn | 2023-06-01 → 2024-05-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥28.5bn | 2023-06-01 → 2023-11-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥5.7bn | 2024-06-01 → 2024-11-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥8.5bn | 2023-06-01 → 2024-05-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥4.6bn | 2023-06-01 → 2023-11-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥182.05 | 2024-06-01 → 2024-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥308.61 | 2023-06-01 → 2024-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥146.27 | 2023-06-01 → 2023-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 50.0% | at 2024-11-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 48.6% | at 2024-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 50.6% | at 2023-11-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
All source rows · 423
| Item | Context | Value | Unit |
|---|---|---|---|
| Name of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)株式会社コスモス薬品 | |
| Address of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)福岡市博多区博多駅東二丁目10番１号 | |
| Information about officers (text) | FilingDateInstant | Text · Plus | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | CurrentYTDDuration | Text · Plus | |
| Type1 semi annual consolidated financial statements financial information | CurrentYTDDuration | Text · Plus | |
| Note on independent audit financial information | CurrentYTDDuration | Text · Plus | |
| Quarterly consolidated balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of income (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of comprehensive income (text) | CurrentYTDDuration | Text · Plus | |
| Quarterly consolidated statement of cash flows (text) | CurrentYTDDuration | Text · Plus | |
| Notes changes in accounting policies in accordance with changes in accounting standards etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes accounting treatments specific to quarterly financial statements quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Major components of selling general and administrative expenses (text) | CurrentYTDDuration | Text · Plus | |
| Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Description of fact that companys business comprises single segment | Prior1YTDDuration | Original text (Japanese)当社グループは医薬品・化粧品等の小売業という単一のセグメントであるため、記載を省略しております。 | |
| Description of fact that companys business comprises single segment | CurrentYTDDuration | Original text (Japanese)当社グループは医薬品・化粧品等の小売業という単一のセグメントであるため、記載を省略しております。 | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |